Scientists in Germany say they've made significant progress with a nasal vaccine that can shut down a Covid-19 infection at its first foothold in the body. The vaccine uses a live but weakened form of the coronavirus, which has shown promising results in hamster studies.
In these experiments, two doses of the vaccine blocked the virus from copying itself in the animals' upper airways, achieving "sterilizing immunity" and preventing illness. This is a long-sought goal of the pandemic, as current vaccines primarily focus on protecting against severe disease rather than halting infection altogether.
While this nasal vaccine still has to pass more tests before it's ready for use, other nasal vaccines are already in use or nearing completion in clinical trials. China and India have rolled out vaccines given through the nasal tissues, but effectiveness data is limited, and researchers are eager to see if these approaches truly work in humans.
The US is currently struggling with the pandemic, with hundreds of Americans still dying daily as Covid-19 continues to simmer in the background of our return to normal life. Researchers hope that next-generation vaccines, which aim to shut down the virus before it makes us sick and prevent its spread, could make a significant difference.
One way scientists are trying to achieve this is by boosting mucosal immunity, enhancing immune defenses in the tissues that line the upper airways, where the virus would land and begin to infect cells. This approach has been tried before, with some success against diseases like anthrax and rabies.
The new nasal vaccine uses a technique called codon pair deoptimization, which manipulates the genetic material of the virus to make it harder for cells to translate. This hobbles the virus so that it can be shown to the immune system without making the body sick.
In hamster studies, the live but weakened vaccine performed better than other types of vaccines, including mRNA-based and adenovirus-facilitated vaccines. The researchers think this is because the vaccine closely mimics the process of a natural infection.
However, caution is warranted, as the vaccine still has to pass more tests before it's ready for use. Vaccine experts say that while the results look encouraging, there are many hurdles to overcome before this vaccine can become widely available.
Other nasal vaccines are also being developed and tested in humans, including one produced cheaply in chicken eggs and another using a live but weakened version of the virus. These studies may provide more insights into the effectiveness of these approaches.
Despite the promise of this technology, there are challenges to consider, such as the difficulty of delivering inhaled vaccines to respiratory infections like flu, which has limited success in adults due to pre-existing immune memory. Still, some potent vaccines use live attenuated viruses, and researchers are optimistic that this approach can be refined to produce effective Covid-19 vaccines.
Ultimately, the goal is to develop a pan-coronavirus vaccine that induces mucosal immunity and is long-lived, which could provide significant protection against Covid-19 and future respiratory infections.
In these experiments, two doses of the vaccine blocked the virus from copying itself in the animals' upper airways, achieving "sterilizing immunity" and preventing illness. This is a long-sought goal of the pandemic, as current vaccines primarily focus on protecting against severe disease rather than halting infection altogether.
While this nasal vaccine still has to pass more tests before it's ready for use, other nasal vaccines are already in use or nearing completion in clinical trials. China and India have rolled out vaccines given through the nasal tissues, but effectiveness data is limited, and researchers are eager to see if these approaches truly work in humans.
The US is currently struggling with the pandemic, with hundreds of Americans still dying daily as Covid-19 continues to simmer in the background of our return to normal life. Researchers hope that next-generation vaccines, which aim to shut down the virus before it makes us sick and prevent its spread, could make a significant difference.
One way scientists are trying to achieve this is by boosting mucosal immunity, enhancing immune defenses in the tissues that line the upper airways, where the virus would land and begin to infect cells. This approach has been tried before, with some success against diseases like anthrax and rabies.
The new nasal vaccine uses a technique called codon pair deoptimization, which manipulates the genetic material of the virus to make it harder for cells to translate. This hobbles the virus so that it can be shown to the immune system without making the body sick.
In hamster studies, the live but weakened vaccine performed better than other types of vaccines, including mRNA-based and adenovirus-facilitated vaccines. The researchers think this is because the vaccine closely mimics the process of a natural infection.
However, caution is warranted, as the vaccine still has to pass more tests before it's ready for use. Vaccine experts say that while the results look encouraging, there are many hurdles to overcome before this vaccine can become widely available.
Other nasal vaccines are also being developed and tested in humans, including one produced cheaply in chicken eggs and another using a live but weakened version of the virus. These studies may provide more insights into the effectiveness of these approaches.
Despite the promise of this technology, there are challenges to consider, such as the difficulty of delivering inhaled vaccines to respiratory infections like flu, which has limited success in adults due to pre-existing immune memory. Still, some potent vaccines use live attenuated viruses, and researchers are optimistic that this approach can be refined to produce effective Covid-19 vaccines.
Ultimately, the goal is to develop a pan-coronavirus vaccine that induces mucosal immunity and is long-lived, which could provide significant protection against Covid-19 and future respiratory infections.